Functional Skills
Project Management
Business Development
Medical Affairs
Strategic Planning
Gene Therapy
Product Strategy
Risk Management
Operational Efficiency
Leadership Development
Good Clinical Practice (GCP)
Communications
Collateral Development
Product Data Management
Product Development
Finance Transformation
Software Skills
Documentum
DocuSign
Dropbox
Google Chrome extensions
Google Docs
Internet Explorer
iPhone
Microsoft Excel
Microsoft PowerPoint
Microsoft Project
Microsoft Office
Microsoft Word
Microsoft Visio
Outlook
Smartsheet
Certifications
MPHMaster of Public Health
Sector Experience
Business Services
Healthcare
Life Sciences & Pharma
Social & Public Sector
Technology
Languages
English
Experience
Adicet Therapeutics
Corporate Strategy & Development
VICE PRESIDENT, PROGRAM DEVELOPMENT
4/2020 - 12/2023
• Acted as a trusted advisor to C-suite executives to build and implement the company’s first integrated drug development operating framework and portfolio governance model, driving strategic alignment, data-driven decision making, resource optimization, competitive analysis, and execution efficiency across a 100+ FTE R&D organization and ~$1B cell therapy pipeline.
• Built and scaled the Program Management Office (PMO), elevating cross-functional transparency, accountability, execution and performance tracking aligned with corporate goals; recruited and developed a high-performing PM team supporting Research, Development and CMC.
• Led development strategy and execution for two novel CAR T-cell programs in oncology and autoimmune diseases, advancing the company from research- to clinical-stage development.
• Managed a strategic alliance with Regeneron, achieving contractual milestones and ensuring joint alignment.
• Built and scaled the Program Management Office (PMO), elevating cross-functional transparency, accountability, execution and performance tracking aligned with corporate goals; recruited and developed a high-performing PM team supporting Research, Development and CMC.
• Led development strategy and execution for two novel CAR T-cell programs in oncology and autoimmune diseases, advancing the company from research- to clinical-stage development.
• Managed a strategic alliance with Regeneron, achieving contractual milestones and ensuring joint alignment.
Nektar Therapeutics
Product Management / Strategy
SENIOR DIRECTOR, PROGRAM MANAGEMENT & HEAD OF ALLIANCE MANAGEMENT
8/2018 - 2/2020
• Oversaw collaborations with Eli Lilly, Bristol Myers Squibb, and other partners, ensuring alignment on joint development goals and facilitating effective execution of joint development programs.
• Implemented alliance governance frameworks to improve decision making and proactive risk management.
• Implemented alliance governance frameworks to improve decision making and proactive risk management.
Nektar Therapeutics
Product Management / Strategy
SENIOR DIRECTOR, PROGRAM MANAGEMENT
7/2016 - 8/2018
• Strategically managed global Phase 3 study execution, an EMA MAA filing, an EMA GCP inspection readiness plan, and a pediatric development plan for Onzeald, etirinotecan pegol (NKTR-102).
• Led collaboration with Daiichi Sankyo Europe, driving alignment between clinical and commercial strategies.
• Drove timely execution of early-stage studies for NKTR-262 and bempegaldesleukin (NKTR-214).
• Contributed to biomarker-informed development strategies for NKTR-102 and NKTR-262, improving patient selection and decision-making.
• Led collaboration with Daiichi Sankyo Europe, driving alignment between clinical and commercial strategies.
• Drove timely execution of early-stage studies for NKTR-262 and bempegaldesleukin (NKTR-214).
• Contributed to biomarker-informed development strategies for NKTR-102 and NKTR-262, improving patient selection and decision-making.
BioMarin Pharmaceutical
Research
DIRECTOR, ONCOLOGY CLINICAL SCIENCES
8/2015 - 1/2016
• Provided clinical leadership for talazoparib external trials, contributing to its global approval as Talzenna.
• Coordinated multi-institutional collaborations with NCI-CTEP, SWOG, FNIH and study investigators to ensure alignment on trial execution, data sharing, and strategic goals.
• Demonstrated scientific and clinical expertise to support execution of a strategic publication plan, ensuring timely and aligned delivery of key publications.
• Coordinated multi-institutional collaborations with NCI-CTEP, SWOG, FNIH and study investigators to ensure alignment on trial execution, data sharing, and strategic goals.
• Demonstrated scientific and clinical expertise to support execution of a strategic publication plan, ensuring timely and aligned delivery of key publications.
BioMarin Pharmaceutical
Research
DIRECTOR, DEVELOPMENT SCIENCES PROJECT MANAGEMENT
6/2014 - 8/2015
• Drove execution of talazoparib company-sponsored oncology trials, integrating biomarker-driven strategies and companion diagnostics to support precision medicine and regulatory readiness.
• Contributed to the content of patient reported outcomes and health technology assessments to support clinical strategy and market access planning.
• Oversaw program budgets, contract approvals, and cross-functional key performance indicators to ensure financial accountability and operational excellence.
• Contributed to the content of patient reported outcomes and health technology assessments to support clinical strategy and market access planning.
• Oversaw program budgets, contract approvals, and cross-functional key performance indicators to ensure financial accountability and operational excellence.